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Purpose: To study safety of children’s glasses in rural China, where fear that glasses harm 
vision is an important barrier for families and policy-makers.  
Design: Exploratory analysis from a cluster-randomized, investigator-masked, controlled 
trial. 
 
Methods: Among primary schools (n=252) in western China, children were randomized 
by school to one of three interventions: free glasses provided in class, vouchers for free 
glasses at a local facility or glasses prescriptions only (Control group). The main outcome 
of this analysis is uncorrected visual acuity after 8 months, adjusted for baseline acuity. 
 
Results: Among 19,934 children randomly selected for screening, 5852 myopic (spherical 
equivalent refractive error <= -0.5 D) eyes of 3001 children (14.7%, mean age 10.5 years) 
had VA <= 6/12 without glasses correctable to > 6/12 with glasses, and were eligible. Among 
these, 1903 (32.5%), 1798 (30.7%), and 2151 (36.8%) were randomized to Control, Voucher 
and Free Glasses respectively. Intention-to-treat analyses were performed on all 1831 
(96.2%), 1699 (94.5%), and 2007 (93.3%) eyes of children with follow-up in Control, 
Voucher and Free Glasses groups. Final visual acuity for eyes of children in the treatment 
groups (Free Glasses and Voucher) was significantly better than for Control children, 
adjusting only for baseline visual acuity (difference of 0.023 logMAR units [0.23 vision chart 
lines, 95% CI: 0.03, 0.43]) or for other baseline factors as well (0.025 logMAR units [0.25 
lines, 95% CI 0.04, 0.45]).  
 
Conclusion: We found no evidence that spectacles promote decline in uncorrected vision 
with aging among children.  
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Introduction 
 Some half of all disability among children in the developing world is due to poor 
vision.
1
 The leading and most readily-treated cause of children’s visual impairment 
(visual acuity <6/18) is refractive error, affecting 12.8 million children aged 5-15 
years world-wide, half of whom live in China.
2
 Chinese children, for whom 
uncorrected refractive error accounts for 90% of visual impairment, have among the 
world’s highest rates of myopia (near-sightedness).3, 4 Uncorrected refractive error is 
associated with worse self-reported visual function among children,
5
 and provision of 
accurate spectacles improves children’s functioning6 and educational outcomes.7  
Spectacles provide an inexpensive and highly effective treatment for refractive error.  
Despite the high prevalence and impact of children’s refractive error in rural 
China, rates of spectacle ownership and wear remain as low as 15% among those 
needing them.
7
 Studies in China
8-9
 and elsewhere
10
 suggest a major reason for this is 
the perception among children, parents and teachers that glasses wear harms children's 
vision by worsening myopia. Concerns about the safety of glasses wear for children 
also influences policy-makers. Government Health and Education Bureau websites in 
China may explicitly advise that children’s glasses wear leads to vision problems,11 or 
fail to recommend glasses as a treatment for myopia due to safety concerns.
12
  
It is known that accurately-measured glasses improve the corrected visual acuity, 
but the concern among many laypersons in China is that wearing glasses will 
eventually worsen a child's uncorrected visual acuity, increasing dependence on their 
wear. It is this latter effect of glasses on the uncorrected vision which is not known. 
Previous small studies
13-5
 have been inconclusive on the effect of glasses wear on 
refractive power, and have not compared wear of glasses with non-wear, or directly 
reported effects on visual acuity.  
We carried out a large, cluster-randomized, population-based trial on the 
educational impact of providing spectacles to children with refractive error in rural 
China.
7
 We now report an exploratory, intention-to-treat analysis of the impact of 
assignment to receive access to free spectacles on uncorrected (without glasses) VA 
over the course of a school year, approximately 8 months. 
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Methods 
 
The protocol for this study was approved in full by Institutional Review Boards at 
Stanford University (Palo Alto, USA) and the Zhongshan Ophthalmic Center of Sun 
Yat-Sen University (ZOC, Guangzhou, China). Permission was received from local 
Boards of Education in each region, and the principals of all schools. The principles 
of the Declaration of Helsinki were followed throughout. The original trial 
(Registration Site: http://isrctn.org. Registration number: ISRCTN03252665) was 
designed to study the effect of providing free spectacles on children's educational 
performance, and found scores on a study-specific mathematic test were statistically 
significantly higher in the group receiving free spectacles compared to controls.
7  
 
The hypothesis of the current exploratory analysis, based on our original trial data, 
is that provision of glasses would slow the decline in uncorrected visual acuity (VA) 
expected to occur due to increase in myopia (near-sightedness) commonly observed 
among children with aging.
16
 The primary outcome of the current analysis is 
uncorrected VA 8 months after provision of spectacles, adjusting for baseline VA. The 
choice of this outcome is based on the fact that uncorrected distance VA is expected to 
worsen with worsening myopia, and that vision itself, rather than refractive power, is 
the outcome of interest from the standpoint of disability and its alleviation. The 
methods of the original trial have been described previously
7
 and are provided here 
for reference. 
 
Setting, sampling and eligibility criteria 
 
The study was carried out in two nearby areas of western China: Tianshui 
prefecture, a poor area in Gansu, one of China’s poorest provinces17-18 and Yulin 
prefecture, Shaanxi, a more affluent region in a middle-income province.
17, 19
 
One school from each township in both prefectures was randomly selected from a list 
of all primary schools, and within each school, one class was randomly chosen in each 
of the 4
th
 and 5
th
 grades. For the original trial, all children at the 252 selected schools 
meeting the following criteria were eligible:   
 
 Uncorrected (without glasses) VA <= 6/12 in either eye 
 Refractive error as follows: 
o Myopia <= -0.75 diopters (D) 
o Hyperopia >= +2.00 D or  
o Astigmatism (Non-spherical refractive error) >= 1.00 D 
 VA could be improved to > 6/12 in both eyes with glasses 
 
In the current analysis, carried out by eye rather than child, all non-myopic (refractive 
error > -0.5 D) eyes of eligible children were excluded. (Figure 1) 
 
Questionnaires 
At baseline (September 2012: beginning of the school year), enumerators 
administered questionnaires to children concerning their age, sex, glasses wear, 
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awareness of their refractive status, boarding at school and parental migration and 
education. A parental questionnaire asked about ownership of 13 selected items as an 
index of family wealth. Mathematics teachers were asked to state whether the 
blackboard was used for all teaching, most, about half, little or none. At closeout 
(May-June 2013: end of the school year) children again filled out a questionnaire on 
glasses wear. Population density was calculated as the total population divided by 
total land area at the township level. 
 
Assessment of Visual Acuity 
 
Children underwent baseline VA screening at school by a nurse and staff assistant, 
previously trained by optometrists from ZOC. VA was tested separately for each eye 
without refractive correction at 4 meters using Early Treatment Diabetic Retinopathy 
Study (ETDRS) charts
20
 (Precision Vision, La Salle, IL, USA) in a well-lighted, 
indoor area. If the orientation of at least four of five optotypes on the 6/60 line was 
correctly identified, children were examined on the 6/30 line, 6/15 and then line by 
line to 6/3. If a line was failed, lines above were tested successively until the child 
identified 4 of 5 optotypes, with the VA for an eye defined as the lowest line read 
successfully. If the top line could not be read at 4 meters, the subject was tested as 
above at 1 meter, and the measured VA was divided by 4.  
 
Refraction (Measurement of glasses power) 
 
 Children with uncorrected visual acuity <= 6/12 in either eye underwent 
cycloplegia with up to three drops of cyclopentolate 1% and automated refraction 
(Topcon KR 8900, Tokyo, Japan) with subjective refinement by a refractionist, 
previously trained by experienced pediatric optometrists from ZOC.  
 
Randomization and Interventions  
 
This was a cluster-randomized, controlled trial, with schools as the clusters. In 
October 2012, after the baseline survey and vision screening but prior to refraction, 
eligible children were randomized by school to receive one of three interventions 
(Figure 1): 
 Free spectacles based on the child's measured refractive power dispensed 
at school by the study optometrist. (Free Glasses group, 84 schools);  
 Vouchers bearing the child's name, school name and glasses prescription, 
exchangeable for free glasses at the local county hospital (distance from 
children’s township: range 1-105 km, median 30 km). Parents were 
responsible for paying transportation costs. (Voucher group, 84 schools); or 
 A glasses prescription and letter to the parents informing them of the 
refractive status of their child, with free glasses provided only at closeout, 
though this was not previously announced. (Control group, 84 schools). 
 
 Schools were stratified by size, county and number of children failing VA 
screening. We used R software (R Foundation for Statistical Computing, Vienna, 
Austria) to generate blocks of and randomly allocate schools within each block to the 
treatment arms.  
 
Outcome Assessment 
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At closeout, VA was assessed using the protocol and vision chart described above. 
Spectacle wear was assessed through unannounced direct examinations on the same 
occasion. Children also described their own spectacle wear as "always," "only for 
studying" or “usually not worn". Study personnel were masked to group assignment. 
Participants (students, parents and teachers) and enumerators were not informed of 
either the overall design of the study or the explicit treatment arm assignment. During 
this visit, all children provided information on parental spectacle wear, and their own 
time spent out of doors and in near/middle distance work, important determinants of 
myopia progression.
16, 21-22 
 
Statistical Methods 
 
Family wealth was calculated by summing the value, as reported in the China 
Rural Household Survey Yearbook (Department of Rural Surveys, National Bureau of 
Statistics of China, 2013), of items on the list of 13 owned by the family. Refractive 
power was defined throughout as the spherical equivalent, the spherical power plus 
half the cylindrical power. 
 
Randomization groups were compared by intention-to-treat (ITT) using multiple 
linear regression, with endline uncorrected VA (log of the minimum angle of 
resolution [logMAR]) as main outcome, and intervention arms and baseline 
uncorrected VA as covariates. Other baseline variables were also investigated as 
predictors for final VA, with the final model including intervention arms and variables 
associated with baseline VA at p<=0.20. Student and school were included in a 
random intercept model to adjust for the correlation between eyes of a student, 
between children in the same school and between schools within the same 
randomization block. All analyses were performed using Stata 12.0 (StataCorp, 
College Station, TX), and SAS 9.3 (SAS Institute, Cary, NC, USA). 
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Results 
 
 Among 19,934 children screened at 252 selected schools, 4839 (24.3%) failed VA 
screening and were randomized (Figure 1). A total of 3177 (65.4%) children (6354 
eyes) in 251 schools were eligible for allocation (VA improving with refraction). 
Among these, 5852 eyes (91.9%) of 3001 children (89.4%) were myopic; their 
baseline characteristics by treatment group are described in Table 1.  
 
Intention-to-treat analyses were performed on all 1831 (96.2%), 1699 (94.5%) 
and 2007 (93.3%) eyes of children completing final VA assessment in the Control, 
Voucher and Free Glasses groups. (Figure 1) Those with follow-up did not differ in 
any baseline variables compared to those without (data not shown).  
 
 Table 2 gives the baseline, endline and change in uncorrected VA by intervention 
group, as well as the effect on endline VA adjusted for baseline VA of membership in 
the Voucher and Free glasses groups compared with the Control group. When children 
in the two treatment groups (Free Glasses and Voucher) were pooled, their endline VA 
adjusted for baseline VA was significantly better than for Control children by 0.023 
(95% CI: 0.003, 0.043) logMAR units (0.23 lines on the VA chart). (Figure 2) 
 
 In multiple linear regression models (Table 3), better uncorrected endline VA was 
associated with: better baseline VA, membership in the Voucher Group or the 
combined treatment groups compared to the Control Group, male sex, and not 
wearing glasses at baseline (the latter presumably indicating that children with better 
VA were less likely to wear glasses). Students in the two treatment groups combined 
had on average 0.025 logMAR units better final VA (0.25 lines, 95% CI 0.04, 0.45, P 
= 0.02) compared to children in the Control group. Time spent in near work and 
outdoor activity, boarding at school, glasses wear by parents, parental education and 
migration status, province of residence, family wealth, use of blackboard in classroom 
teaching and population density of the township of residence were not significantly 
associated with endline VA. 
 
Only 15% (441/3001) of these children needing glasses were wearing them at 
baseline. Endline glasses wear was 42% (observed: 439/1053) to 69% (self-reported: 
730/1053) in the Free Glasses group; 38% (observed: 334/887) to 65% (self-reported: 
574/887) among the Voucher group; and 26% (observed: 241/944) to 38% 
(self-reported: 355/944) among Controls. 
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Discussion 
 
 Results from intention-to-treat analysis in this randomized trial suggest that 
provision of spectacles does not promote the decline in uncorrected VA expected from 
increasing myopia with age
16
 among children. Concern over such potential harm is 
widespread in China,
8-10
 and has been identified as an important barrier to use of 
glasses by children needing them there
8-9
 and elsewhere.
23-4
   
 
 This study provides the strongest evidence to date of the visual safety of spectacle 
wear for children. While the mean beneficial effect on VA of one-quarter line over a 
school year was modest, this effect size reflects all children randomized to receive 
treatment, whether glasses were used or not. Compliance rates in the treatment groups 
were 40-70% and conversely, a quarter to a third of children in the Control group had 
obtained glasses by the time of the final examination. Strategies to improve spectacle 
compliance could realize a greater impact on vision protection. We are currently 
testing teacher incentives as a means to improve children's classroom wear of glasses 
in a trial in Shanghai. The cumulative impact on vision protection over time may also 
be greater, though studies are needed to confirm this. 
 
 We searched the PubMed database in January 2014 for articles describing 
randomized trials in any language published since 1970, using the terms "correction," 
"glasses" and "spectacles" cross-indexed with "refractive error" and "myopia"; 
"change," "decline," "effect" and "impact;" and "vision" and "visual acuity." Two 
previous small (total of < 200 children) trials
14-5
 compared the effect on change in 
refractive power over 18-24 months of full correction of refractive error with glasses 
to provision of glasses with power lower by 0.50-0.75 D than needed for optimal 
distance VA. The hypothesis of these studies was that lower-power glasses would be 
protective against the worsening of myopia with aging. The two studies actually found 
less progression of refractive error in the full-power group by 0.15 D,
14-5
 an effect that 
was significant when the results were pooled in a subsequent Cochrane review.
13 
These studies did not randomize children to go without glasses altogether, report on 
VA or include many Chinese children (41 participants [44%] in Chung et al
15
). 
Current sparse trial evidence is thus consistent in suggesting that correction of 
refractive error with glasses may be protective against, or us at least unlikely to 
worsen, declines in VA due to myopic progression with aging in children.  
 
The factors underlying this tendency for myopia to worsen with age are not fully 
understood, but are thought to be controlled by dopaminergic pathways,
25
 mediated by 
factors including time spent in near work and outdoors,
16, 21-2
 and the stimulus of 
defocused light falling on the peripheral retina.
26
 Wear of conventional spectacles 
does appear to contribute to this peripheral defocus,
27-8
 which provided the impetus 
for the randomized trials of under-correction in preventing myopia progression as 
cited above.
14-5
 The mechanism whereby spectacle wear (compared to non-wear) 
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appears in fact to retard worsening of vision associated with progression of myopia is 
not well understood. 
 
 Recent evidence suggests that optical correction designed specifically to prevent 
defocused light from falling on the peripheral retina may further retard age-related 
increase in myopic refractive error in children, when compared to conventional 
glasses and contact lenses.
29
 These devices are still not widely available, and are quite 
expensive compared to conventional glasses. Though not at present appropriate for 
large-scale treatment programs, they may eventually offer an even greater vision 
protection benefit.  
 
 The strengths of the current study include its population-based sampling, 
randomized design and high follow-up rates, all of which increase confidence in the 
results. Weaknesses must also be acknowledged: VA not was not a pre-specified 
outcome of trial, compliance with spectacle wear was less than perfect and refractive 
power was not assessed at endline, precluding comparison of change in refractive 
power between groups over the study period. However, from the point of view of 
visual functioning and education, visual acuity rather than refractive error is the 
principal outcome of interest. All schools and children enrolled were drawn from two 
nearby prefectures in northwestern China, so that application of these findings to other 
settings must be made with caution. 
 
 Uncorrected refractive error is the leading cause of visual impairment among 
children world-wide.
2
 The results of this study provide strong evidence of the visual 
safety of medium-term spectacle wear for myopic children. Taken together with the 
main trial result demonstrating statistically-significant improvements in educational 
outcomes with spectacle provision,
7
 the current result provides further impetus for 
programs to provide spectacles for children needing them, particularly in China where 
the myopia problem is greatest.  
 
 Previous randomized studies in China have shown that interventions aimed at 
explaining to children, their teachers and parents that glasses wear is beneficial and 
safe have had no
30
 or very modest
7
 effects on uptake. A more immediate effect may be 
realized on policy-makers concerned over spectacle safety:
11-12
 On the basis of our 
results to date,
7
 authorities in Shaanxi and Gansu Provinces, where the study was 
conducted, have already authorized county-wide models of free glasses distribution, 
with potential for expansion throughout both provinces.  
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Figure Legends 
 
Figure 1: Enrollment and progress of children through a randomized trial on the 
effects of the provision of spectacles to Chinese school-aged children 
 
Figure 2.  Change in visual acuity over one school year stratified by intervention 
group in a randomized trial on the effects of the provision of spectacles to Chinese 
school-aged children. Though higher values on the logMAR scale indicate worse 
vision, we have followed the convention in this figure that negative change indicates 
worsening and positive change indicates improvement. 
 
A total of 10 outliers (4 Control, 6 Voucher/Free glasses) were excluded from the 
figure. 
 
Table 1. Baseline characteristics of 5852 eyes of 3001 children with correctable myopia 
allocated in a trial of spectacle provision, by treatment group assignment.  
Characteristic 
 
 
Control 
Group 
Voucher 
Group 
Free Glasses 
Group 
Treatment 
groups 
combined 
(Voucher + 
Free) 
Missing 
data (%) 
  n=1903* n=1798* n=2151* n=3949*  
Age (years) 10.5 (1.1) 10.5 (1.1) 10.4 (1.1) 10.5 (1.1) 4 (0.07) 
Male sex (%) 948 (49.8) 857 (47.7) 1040 (48.4) 1897 (48.0) 0 (0) 
Degree of myopia (Diopters [D]):     0 (0) 
<=-0.5 and  >-1.0 182 (9.6) 206 (11.5) 265 (12.3) 471 (11.9)  
<=-1.0 and  >-1.5 489 (25.7) 421 (23.4) 537 (25.0) 958 (24.3)  
<=1.5 and  >-2.0 383 (20.1) 382 (21.2) 437 (20.3) 819 (20.7)  
<=-2.0 849 (44.6) 789 (43.9) 912 (42.4) 1701 (43.1)  
Baseline uncorrected visual acuity 
(LogMAR) † 
0.6 (0.2) 0.6 (0.2) 0.6 (0.2) 0.6 (0.2) 0 (0) 
Having glasses at baseline (%)†† 270 (14.2) 262 (14.6) 349 (16.2) 611 (15.5) 0 (0) 
Total time spent in near-work 
(hours/week) 
7.3 (3.6) 7.5 (3.7) 7.4 (3.6) 7.5 (3.7) 4 (0.07) 
Total time spent in middle distance 
activities (hours/week) 
4.9 (4.2) 5.2 (4.3) 5.2 (4.5) 5.2 (4.4) 12 (0.21) 
Total time spent in outdoor activities 
(hours/week) 
7.9 (3.8) 8.0 (4.0) 8.0 (4.1) 8.0 (4.0) 11 (0.20) 
Boarding at school (%) 442 (23.2) 336 (18.7) 546 (25.4) 882 (22.4) 3 (0.05) 
One or more parents wearing glasses (%) 676 (35.6) 561 (32.7) 780 (36.3) 1372 (34.8) 14 (0.25) 
One or both parents with >= 12 years of 
education (%) 
384 (20.3) 315 (17.7) 490 (23.1) 805 (20.7) 58 (1.03) 
Both parents out-migrated for work (%) 207  (11.0) 182 (10.2) 195 (9.2) 377 (9.6) 52 (1.03) 
Gansu residence (%) 704 (37.0) 647 (36.0) 732 (34.0) 1379 (34.9) 0 (0) 
Family wealth:     227 (4.04) 
Bottom tercile  578 (32.0) 619 (36.2) 664 (31.9) 1283 (33.8)  
Middle tercile  659 (36.5) 567 (33.1) 643 (30.9) 1210 (31.9)  
Top tercile  567 (31.4) 525 (30.7) 775 (37.2) 1300 (34.3)  
Blackboard use in class:     0 (0) 
             Less than half of teaching 498 (27.0) 458 (26.6) 824 (40.0) 1282 (33.9)  
             Half 780 (42.3) 700 (40.7) 645 (31.3) 1345 (35.6)  
             More than half 567 (30.7) 563 (32.7) 590 (28.7) 1153 (30.5)  
Population density:     0 (0) 
            1st quartile 450 (23.7) 295 (16.4) 598 (27.8) 893 (22.6)  
            2nd quartile 501 (26.3) 484 (26.9) 577 (26.8) 1061 (26.9)  
            3rd quartile 343 (18.0) 467 (26.0) 459 (21.3) 926 (23.4)  
            4th quartile 609 (32.0) 552 (30.7) 517 (24.1) 1069 (27.1)  
logMAR = log of the Minimum Angle of Resolution 
*Data are presented as mean (SD) or number (%) unless otherwise stated.  
† 0.1 change in logMAR indicates 1 line change on the vision chart. 
†† Defined as having glasses at school at baseline, having previously been told to bring them to 
school.  
All Tables
Table 2.  Effect of treatment arms in a trial of spectacle provision on final uncorrected visual acuity (LogMAR) of both eyes.  
 
  
Mean baseline  
uncorrected  
logMAR visual acuity  
(SD) 
Mean endline 
uncorrected  
logMAR visual acuity 
 (SD) 
Unadjusted change in 
logMAR visual acuity  
(95% CI) 
Effect of interventions on endline 
uncorrected visual acuity adjusted for 
baseline acuity (95% CI)* 
Intervention group N     
TOTAL 5537 0.59 (0.22) 0.71 (0.21) 
-0.12* 
(-0.14, -0.10) 
- 
      
Control 1831 0.60 (0.22) 0.73 (0.21) 
-0.13* 
(-0.15, -0.10) 
(Reference) 
      
Voucher 1699 0.58 (0.22) 0.70 (0.21) 
-0.11* 
(-0.13, -0.09) 
0.028* 
(0.004, 0.052) 
      
Free Glasses 2007 0.59 (0.21) 0.71 (0.20) 
-0.12* 
(-0.14, -0.10) 
0.02 
(-0.01, 0.04) 
      
Treatment groups(Voucher + 
Free glasses) combined 
3706 0.58 (0.21) 0.71 (0.20) 
-0.11* 
(-0.13, -0.10) 
0.023* 
(0.003, 0.043) 
      
 
Though higher values on the logMAR scale indicate worse vision, we have followed the convention in this table that negative change indicates worsening and 
positive change indicates improvement 
 
logMAR = log of the Minimum Angle of Resolution 
* Indicates P < 0.05 
SD Standard deviation 95%  
CI Confidence Interval 
 Table 3: Linear regression model of potential predictors of final uncorrected logMAR* visual acuity.  
 
Characteristics 
 
Model adjusted only for baseline 
visual acuity (n=5537) 
 
Full model‡ (n=5498) 
Regression 
coefficient†¶ (95% 
CI)  
 
P-value 
Regression 
coefficient¶ (95% CI) 
 
P-value 
Baseline uncorrected visual acuity (LogMAR) 0.540 (0.520, 0.561) < 0.001 0.515 (0.493, 0.537) < 0.001 
Intervention group (Control group as reference)     
Voucher Group 
0.028 (0.004,  
0.052) 
0.02 0.029 (0.006, 
 0.053) 
0.02 
Free Glasses Group 0.018 (-0.005, 0.042,) 0.13 0.020 (-0.003, 0.044) 0.09 
Treatment groups (Voucher + Free glasses)            
0.023 (0.003, 
 0.043) 
0.03 0.025 (0.004, 0.004) 0.02 
Age (years) 
-0.005 (-0.009, 
0.0001) 
0.06 -0.004 (-0.008, 
0.001) 
0.15 
Male sex 
0.015 (0.005, 
 0.024) 
< 0.001 0.013 (0.003, 
 0.023) 
0.01 
Wearing glasses at baseline† 
-0.049 (-0.064,       -
0.034) 
< 0.001 -0.047 (-0.062,      -
0.032) 
< 0.001 
 
    
Total time spent in near-work 
(hours/week) 
-0.0001 (-0.002, 
0.001) 
0.65   
Total time spent in midworking distance activities 
(hours/week) 
0.001 (-0.0001, 0.002) 0.12 0.001 (-0.001, 0.002) 0.27 
Total time spent in outdoor activities (hours/week) 0.001 (-0.0001, 0.002) 0.17 0.001 (-0.001, 0.002) 0.28 
Boarding at school 
-0.0001 (-0.014, 
0.015) 
0.98   
At least one other family member wearing glasses 
-0.013 (-0.024,       -
0.003) 
0.01 -0.010 (-0.021, 
0.0001) 
0.06 
One or both parents with >= 12 years of education -0.004 (-0.017, 0.008) 0.50   
Both parents out-migrated for working 0.002 (-0.014, 0.019) 0.78   
Gansu residence 0.024 (-0.005, 0.052) 0.11 0.021 (-0.006, 0.049) 0.13 
Family wealth (Bottom tercile as reference)     
Middle tercile -0.008 (-0.020, 0.005) 0.22   
Top tercile 0.008 (-0.005, 0.022) 0.21   
Blackboard use in class (Less than half as reference)     
Half 
-0.015 (-0.031, 0.002) 0.08 -0.014 (-0.031, 
0.002) 
0.09 
More than half 0.005 (-0.012, 0.023) 0.55 0.004 (-0.014, 0.022) 0.64 
Population density (1st quartile as reference)     
2nd quartile 0.001 (-0.031, 0.033) 0.98   
3rd quartile -0.013 (-0.048, 0.022) 0.31   
4th quartile -0.015 (-0.050, 0.019) 0.61   
 
Though higher values on the logMAR scale indicate worse vision, we have followed the convention in this table that negative change indicates worsening and 
positive change indicates improvement 
* logMAR = log of Minimum Angle of Resolution 
† Except for the regression coefficient for baseline visual acuity (simple regression), coefficients for the different variables are for multiple models with endline 
visual acuity as dependent variable, adjusted for baseline visual acuity 
‡Including variables associated with visual acuity p<= 0.20 in the model only adjusted for baseline visual acuity 
¶ A negative regression coefficient indicates an association with worse endline visual acuity  
CI Confidence Interval 
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CONSORT 2010 checklist of information to include when reporting a randomised trial 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2-3 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 4 
2b Specific objectives or hypotheses 5 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 8 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants 6-7 
4b Settings and locations where the data were collected 6 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
8-9 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
9 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 9 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 8 
8b Type of randomisation; details of any restriction (such as blocking and block size) 8 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
8 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
8 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 9 
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assessing outcomes) and how 
11b If relevant, description of the similarity of interventions 8 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 9-10 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 9-10 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
11, Fig 1 
13b For each group, losses and exclusions after randomisation, together with reasons 11, Fig 1 
Recruitment 14a Dates defining the periods of recruitment and follow-up Recruitment : 
7 
Follow-up: 9 
14b Why the trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table 1 (22-
23) 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
Figure 1, p. 
11 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
11-12 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 12, Table 3 
(26) 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
12 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) N/A 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 13-14 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 13-14 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 15 
Other information  
Registration 23 Registration number and name of trial registry Title page (1), 
Abstract (3) 
Protocol 24 Where the full trial protocol can be accessed, if available Provided as 
separate 
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submission 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 17 
 
 
